Quick Answer
Boundless Bio, Inc. reported R&D Expense of $44.84 million for fiscal year 2025.
Boundless Bio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $44.84M | -18.9% |
| 2024 | $55.27M | +29.6% |
| 2023 | $42.64M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.67M | -24.2% | -12.6% |
| June 30, 2025 | $12.22M | -17.1% | +0.7% |
| March 31, 2025 | $12.14M | -7.5% | -13.8% |
| September 30, 2024 | $14.09M | +21.0% | -4.4% |
| June 30, 2024 | $14.73M | +33.0% | +12.2% |
| March 31, 2024 | $13.13M | +38.2% | +12.7% |
| September 30, 2023 | $11.64M | — | +5.1% |
| June 30, 2023 | $11.07M | — | +16.5% |
- Boundless Bio, Inc. showed a decrease of -18.9% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Boundless Bio, Inc.’s r&d expense has grown by 5.2% (from $42.64 million to $44.84 million).
- The most recent figure is from Boundless Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: